Floatz logo

Inno-206

Ann Arbor Stage II Marginal Zone Lymphoma

Mayo ClinicPhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

105 Active assets in the Ann Arbor Stage II Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB

View all 50 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →